Isolation of Progenitors that Exhibit Myogenic/Osteogenic Bipotency In Vitro by Fluorescence-Activated Cell Sorting from Human Fetal Muscle

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters.


Citable link: http://nrs.harvard.edu/urn-3:HUL.InstRepos:25139393

Terms of Use: This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Isolation of Progenitors that Exhibit Myogenic/Osteogenic Bipotency In Vitro by Fluorescence-Activated Cell Sorting from Human Fetal Muscle

Alessandra Castiglioni,1,2,3 Simone Hettmer,1,2,4,7 Matthew D. Lynes,2 Tata Nageswara Rao,1,2 Daria Tchessalova,1,2 Indranil Sinha,5 Bernard T. Lee,6 Yu-Hua Tseng,2 and Amy J. Wagers1,2,*

1Howard Hughes Medical Institute, Department of Stem Cell and Regenerative Biology, Harvard University, Harvard Stem Cell Institute, Cambridge, MA 02138, USA
2Joslin Diabetes Center and the Paul F. Glenn Laboratories for the Biological Mechanisms of Aging, Harvard Medical School, Boston, MA 02115, USA
3Vita-Salute San Raffaele University, Milan 20132, Italy
4Department of Pediatric Oncology, Dana Farber Cancer Institute and Division of Pediatric Hematology/Oncology, Children’s Hospital, Boston, MA 02115, USA
5Division of Plastic Surgery, Brigham and Women’s Hospital, Boston, MA 02115, USA
6Division of Plastic and Reconstructive Surgery, Department of Surgery, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
7These authors contributed equally to this work
*Correspondence: amy_wagers@harvard.edu

http://dx.doi.org/10.1016/j.stemcr.2013.12.006

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

SUMMARY

Fluorescence-activated cell sorting (FACS) strategies to purify distinct cell types from the pool of fetal human myofiber-associated (hMFA) cells were developed. We demonstrate that cells expressing the satellite cell marker PAX7 are highly enriched within the subset of CD45+/CD11b−GlyA+/CD31−CD34−CD56intITGA7hi hMFA cells. These CD45+/CD11b−GlyA+/CD31−CD34−CD56intITGA7hi cells lack adipogenic capacity but exhibit robust, bipotent myogenic and osteogenic activity in vitro and engraft myofibers when transplanted into mouse muscle. In contrast, CD45+/CD11b−GlyA−CD31−CD34− fetal hMFA cells represent stromal constituents of muscle that do not express PAX7, lack myogenic function, and exhibit adipogenic and osteogenic capacity in vitro. Adult muscle likewise contains PAX7+/CD45−/CD11b−GlyA−CD31−CD34−CD56intITGA7hi hMFA cells with in vitro myogenic and osteogenic activity, although these cells are present at lower frequency in comparison to their fetal counterparts. The ability to directly isolate functionally distinct progenitor cells from human muscle will enable novel insights into muscle lineage specification and homeostasis.

INTRODUCTION

In mice, combinatorial surface marker analysis has been useful in enabling direct discrimination and prospective isolation of phenotypically and functionally distinct cells from skeletal muscle using fluorescence-activated cell sorting (FACS) (Cerletti et al., 2008; Kuang et al., 2007; Sacco et al., 2008; Sherwood et al., 2004; Tanaka et al., 2009). FACS has been used to purify PAX7-expressing mouse satellite cells, which exhibit self-renewal and myogenic differentiation capacities consistent with muscle stem cells (Cerletti et al., 2008; Fukada et al., 2004; Kuang et al., 2007; Montarras et al., 2005; Sacco et al., 2008; Sherwood et al., 2004; Tanaka et al., 2009). Prospective isolation of adult mouse satellite cells has also enabled studies that distinguished their myogenic differentiation potential from adipogenic/fibrogenic activities in muscle (Joe et al., 2010), revealed their contributions to muscle pathologies (Cerletti et al., 2008; Chakkalakal et al., 2012; Conboy et al., 2003; Sacco et al., 2008), and provided proof in principle that they may be useful in cell therapy approaches (Cerletti et al., 2008, 2012; Sacco et al., 2008). A similar cell-sorting approach recently allowed purification of fibroadipogenic precursors from mouse muscle and showed that these cells lack myogenic capacity (Joe et al., 2010; Uezumi et al., 2010). Together with endothelial and infiltrating immune cells, these fibroadipogenic precursors constitute the muscle stroma and play a critical role in regulating the early stages of muscle repair after damage (Wang and Rudnicki, 2012). However, in order to translate these findings to human muscle and apply them for regenerative medicine, it is essential to develop analogous strategies for prospective identification and isolation of human myogenic and adipogenic precursors.

Lecourt et al. previously showed by immunofluorescence (IF) staining that cells in the satellite cell position in adult human muscle lack CD34 (Lecourt et al., 2010). Pisani et al. subsequently demonstrated that myogenic activity could be enriched in human adult muscle cells by magnetic depletion of CD34+ cells (Pisani et al., 2010b). However, as described here, negative selection for CD34 achieves only partial purification of myogenic progenitors from human fetal muscle. To establish more specific sorting strategies capable of purifying human PAX7-positive cells, we undertook a systematic study of surface markers that distinguish phenotypically and functionally distinct cells in human fetal muscle. These efforts identified a combination of...
seven surface markers that reliably discriminate a purified population of PAX7-expressing CD45$^-$/CD11b$^-$/GlyA$^-$/CD31$^-$/CD34$^-$/CD56$^{int}$/ITGA7$^{hi}$ human myofiber-associated (hMFA) cells (hereafter referred to as CD34$^-$/CD56$^{int}$/ITGA7$^{hi}$ cells) from infiltrating blood cells and muscle-resident adipogenic precursors, allowing direct isolation of each of these populations by FACS. Consistent with studies in the mouse, human PAX7-expressing CD34$^-$/CD56$^{int}$/ITGA7$^{hi}$ cells are robustly myogenic and lack adipogenic potential. PAX7-expressing CD34$^-$/CD56$^{int}$/ITGA7$^{hi}$ cells with myogenic activity in vitro are also present in adult muscle, but at lower frequency than in fetal tissue. Clonal analysis in vitro further revealed a surprising bipotency of human fetal PAX7-expressing CD34$^-$/CD56$^{int}$/ITGA7$^{hi}$ cells, which exhibited both myogenic and osteogenic potential. In contrast, CD45$^-$/CD11b$^-$/GlyA$^-$/CD31$^-$/CD34$^+$ fetal hMFA cells (abbreviated CD34$^+$ cells), which exhibited potent adipogenic and osteogenic activity, lack PAX7 and show no myogenic potential. Taken together, these studies report efficient methods for the direct isolation of highly enriched human fetal bipotent myogenic/osteogenic and adipogenic progenitors. These protocols provide tools for uncovering the cellular mechanisms and environmental interactions that sustain human skeletal muscle.

RESULTS

Human Fetal Skeletal Muscle Contains Multiple, Distinct Cell Populations

To evaluate phenotypic and functional heterogeneity among fetal hMFA cells, we adapted previously established protocols for mouse myofiber-associated cell isolation (Conboy et al., 2003; Sherwood et al., 2004) to liberate the mononuclear cell fraction from human fetal muscle (Ehrhardt et al., 2007; Tanaka et al., 1995). Plating hMFA cells under myogenic, adipogenic, or osteogenic conditions in vitro revealed significant functional heterogeneity. Under myogenic conditions, hMFA cells formed DESMIN-expressing multinucleated myotubes. Under adipogenic conditions, hMFA cells differentiated into oil red O (ORO)-positive, lipid droplet-containing adipocytes. Under osteogenic conditions, hMFA cells produced Alizarin-red (AR)-positive calcium deposits consistent with osteogenic differentiation (Figure 1A).

We next evaluated phenotypic heterogeneity within the hMFA pool using cell surface marker staining and FACS. Existing literature was surveyed to identify candidate antigenic markers that might discriminate live myogenic from nonmyogenic cells (Fukada et al., 2004; Kuang et al., 2007; Lecourt et al., 2010; Pisani et al., 2010a, 2010b; Sacco et al., 2008; Sherwood et al., 2004). PAX7, the canonical marker of muscle satellite cells in mouse and human postnatal muscle (Bosnakovski et al., 2008; Seale et al., 2000), is inappropriate for such an approach because as a nuclear protein, antibody staining requires cell fixation/permeabilization. Flow cytometric analysis of hMFA cells revealed differential expression of 11 candidate cell surface markers (CD45, CD11b, glycoporphin A [GlyA], β1 integrin, CD34, CD56, ITGA7, CD90, CD13, and CXCR4; Figure 1B and Figure S1A available online). A total of 9.1% ± 1.7% (mean ± SD) of fetal hMFA cells expressed hematopoietic lineage markers (CD45, CD11b, and GlyA) and CD31, an endothelial marker (Figure 1B) (Andukuri et al., 2013). Expression of CD34, CD56, and ITGA7 was detected in 55% ± 10.8%, 40.5% ± 7.0%, and 55.9% ± 9.2% of cells, respectively (mean ± SD; Figures 1B and S1A–S1C). Other markers analyzed included CD29, CD90, CD13, and CXCR4, which were expressed by 90.4% ± 9.4% (CD29), 63.9% ± 10.3% (CD90), 38.4% ± 3.8% (CD13), and 63.2% ± 10.3% (CXCR4) of cells, respectively (mean ± SD; Figures 1B and S1D–S1F). These analyses confirmed heterogeneity of cell surface marker expression by fetal hMFA cells. We therefore sought to exploit this heterogeneity to fractionate fetal hMFA subsets with distinct differentiation potentials.

CD45$^-$/CD11b$^-$/GlyA$^-$/CD31$^-$/CD34$^-$/CD56$^{int}$/ITGA7$^{hi}$ Fetal hMFA Cells Are Enriched for PAX7-Expressing Cells

Satellite cells are canonically recognized by expression of the paired box transcription factor PAX7, which controls transcription of myogenic genes such as MyoD and Myf5 (McKinnell et al., 2008) and is present in satellite cells as well as muscle progenitors in postnatal muscle tissue. A total of 27.5% ± 1% (mean ± SD) of fetal hMFA cells expressed PAX7 by IF analysis (Figures 2B and S2). To assess PAX7 expression by IF in fetal hMFA cell subsets, cells were isolated by FACS after combinatorial staining for differentially expressed cell surface markers (Figure 1C). Exclusion of cells expressing CD45, CD11b, GlyA, and CD31 (which mark hematopoietic and endothelial lineage cells) and selection of CD34$^{+/low}$ cells identified a population enriched for PAX7-expressing cells (55% ± 5% PAX7$, mean ± SD; Figure 2B). These CD45$^-$/CD11b$^-$/GlyA$^-$/CD31$^-$/CD34$^{+/low}$ cells are hereafter designated “CD34$^{+/low}$ cells” (marked in pink in Figure 1C). None of the CD45$^-$/CD11b$^-$/GlyA$^-$/CD34$^+$ cells (hereafter designated “CD34$^+$ cells” and marked in cyan in Figure 1C) expressed PAX7 (Figure 2). Thus, CD34$^{+/low}$ hMFA cells from fetal muscle are selectively enriched for PAX7-expressing cells.

To further enrich PAX7$^+$ cells within the CD34$^{+/low}$ hMFA cell subset, we evaluated expression of additional surface markers (Figure 1B). Differential expression of
CD90, CD13, and CD29 did not discriminate candidate populations within the CD34−/low hMFA cell pool, as CD90 and CD13 expression was enriched in the CD34+ cell subset and CD29 was uniformly expressed by CD34−/low cells (data not shown). In contrast, differential expression of CD56 and ITGA7 distinguished three populations within CD34−/low fetal hMFA cells: CD34−CD56hiITGA7low (marked in blue in Figure 1C), CD34−CD56intITGA7hi (marked in red in Figure 1C), and CD34−/low CD56−ITGA7low (marked in green in Figure 1C). In addition to differences in CD56 and ITGA7 expression, variable low-level expression of CD34 was noted in CD34−/low CD56−ITGA7low hMFA cells, compared to absent CD34 expression in CD34+CD56intITGA7hi and CD34−CD56hiITGA7low cells (Figure S1H). PAX7 IF showed clear enrichment of PAX7+ cells (78.3% ± 5%, mean ± SD) in the CD34−CD56intITGA7hi subset (Figure 2; red gate in Figure 1C). In contrast, we detected no PAX7 expression in CD34+CD56intITGA7low cells (Figures 2B and S2; blue gate in Figure 1C) and variable PAX7 expression in CD34−/lowCD56−ITGA7low cells (33.0% ± 28%, mean ± SD; Figures 2B and S2; green gate in Figure 1C).

All cell populations were sorted twice to maximize purity. The purity of double-sorted CD34+, CD34−/low, CD34−CD56hiITGA7low, and CD34+CD56intITGA7hi cells was consistently >99% upon reanalysis (Figure S3); however, reanalysis of sorted CD34−/lowCD56−ITGA7low cells showed variable purities of 68.1% ± 26% (mean ± SD; Figure S3). Variable contamination with CD34+CD56intITGA7hi cells could explain the variable levels of PAX7 expression detected in the sorted CD34−/lowCD56−ITGA7low cells. In contrast, PAX7 enrichment in CD34−CD56intITGA7hi cells and absent PAX7 expression in CD34+CD56intITGA7low was highly reproducible (n = 6 distinct donors for CD34−CD56intITGA7hi cell analysis and n = 3 donors for CD34−CD56intITGA7low cell analysis; Figure 2B). Thus, the canonical satellite cell marker PAX7 is selectively enriched in CD34−CD56intITGA7hi fetal hMFA cells, suggesting that human myogenic progenitors may be contained in this population.
CD34<sup>+</sup>CD56<sup>int</sup>ITGA<sup>7hi</sup> Fetal hMFA Cells Exhibit Myogenic and Osteogenic Activity In Vitro but Lack Adipogenic Differentiation Potential

We next evaluated the lineage potential of the fetal hMFA cell subsets identified above using in vitro differentiation assays. Under myogenic conditions (Figure 3, left panels), CD34<sup>-</sup> and CD34<sup>-/low</sup> and CD34<sup>-/low</sup>CD56<sup>int</sup>ITGA<sup>7hi</sup> cells exhibited efficient myogenic differentiation, as evidenced by large numbers of DESMIN<sup>+</sup> multinucleated myotubes. In contrast, CD34<sup>-/low</sup>CD56<sup>-/low</sup>ITGA<sup>7low</sup> cells showed minimal myogenic capacity. CD34<sup>+</sup> and CD34<sup>-/low</sup>CD56<sup>hi</sup>ITGA<sup>7low</sup> cells, both of which lack PAX7 expression (Figure 2), exhibited no myogenic activity. Under adipogenic conditions (Figure 3, central panels), both CD34<sup>+</sup> and CD34<sup>-/low</sup> cells formed adipocytes (containing ORO-staining lipid droplets). Within the CD34<sup>-/low</sup> subset, only CD34<sup>-/low</sup>CD56<sup>int</sup>ITGA<sup>7low</sup> cells contained adipogenic activity, while CD34<sup>-/low</sup>CD56<sup>int</sup>ITGA<sup>7hi</sup> and CD34<sup>-/low</sup>CD56<sup>hi</sup>ITGA<sup>7low</sup> cells were uniformly nonadipogenic. These data suggest that CD34<sup>-/low</sup>CD56<sup>int</sup>ITGA<sup>7low</sup> cells are responsible for the adipogenic differentiation potential present among CD34<sup>-/low</sup> fetal hMFA cells. Finally, under osteogenic conditions (Figure 3, right panels), both CD34<sup>+</sup> and CD34<sup>-/low</sup> cells formed AR-staining calcium deposits, consistent with osteogenic differentiation. Myogenic CD34<sup>-CD56<sup>int</sup>ITGA<sup>7hi</sup> and CD34<sup>-/low</sup>CD56<sup>int</sup>ITGA<sup>7low</sup> cells also exhibited osteogenic activity in these in vitro assays (Figure 3B, right panels).

Differences in the myogenic and adipogenic differentiation capacity of fetal CD34<sup>-</sup>CD56<sup>int</sup>ITGA<sup>7hi</sup> cells and CD34<sup>+</sup> cells remained evident under all the culture conditions used. Specifically, myogenic CD34<sup>-</sup>CD56<sup>int</sup>ITGA<sup>7hi</sup> cells still formed multinucleated myotubes under adipogenic (Figure S4A) and osteogenic (Figures 3B and S4B) conditions and never formed adipocytes (Figures S4A and S4B). In contrast, CD34<sup>+</sup> cells formed adipocytes under adipogenic (Figures 3 and S4A) and osteogenic (Figure S4B) conditions and never formed myotubes (Figures 3 and S4A). Under myogenic conditions, CD34<sup>+</sup> cells adopted fibroblastic morphology (data not shown).

In summary, these experiments reveal the following differences in the in vitro myogenic, adipogenic, and osteogenic potentials of discrete, prospectively isolatable fetal hMFA cell subsets: (1) PAX7-negative, CD34<sup>-CD56<sup>int</sup>ITGA<sup>7hi</sup> cells lack myogenic, adipogenic, and osteogenic activity (Figures 2 and 3B); (2) PAX7-negative, CD34<sup>+</sup> cells contain adipogenic and osteogenic activity but lack myogenic capacity (Figure 2 and Figure 3A); and
PAX7-positive, CD34<sup>−</sup>CD56<sup>int</sup>ITGA<sub>7</sub>hi cells (Figure 2) contain myogenic and osteogenic capacity (Figure 4) but lack adipogenic potential (Figure 3B).

**Human Fetal CD34<sup>−</sup>CD56<sup>int</sup>ITGA<sub>7</sub>hi Cells Exhibit Bipotent Myogenic/Osteogenic Differentiation Activity In Vitro**

The ability of PAX7-positive, CD34<sup>−</sup>CD56<sup>int</sup>ITGA<sub>7</sub>hi human fetal cells to efficiently undergo myogenic differentiation in vitro and form AR-positive calcium deposits indicative of osteogenic differentiation is consistent with previous reports of hMFA osteogenic differentiation (Hashimoto et al., 2008; Lecourt et al., 2010; Oishi et al., 2013). To determine whether this observation reflects true bipotency, we clone-sorted CD34<sup>−</sup>CD56<sup>int</sup>ITGA<sub>7</sub>hi cells into 96-well plates (one cell per well) and expanded them for parallel analysis of myogenic and osteogenic activity in vitro (Figure 4A). The efficiency of CD34<sup>−</sup>CD56<sup>int</sup>ITGA<sub>7</sub>hi fetal hMFA cell clonal expansion was variable and donor dependent, with an average seeding efficiency of 7.1% ± 5.4% (mean ± SD; Figure 4B). We succeeded in expanding 18 clones from four donors. After 14–22 days of expansion, these 18 clones were split and replated under myogenic or osteogenic differentiation conditions. Under myogenic conditions, 100% (Figure 4B) of clones differentiated into DESMIN-positive myotubes (Figure 4C; one representative clone shown). Under osteogenic conditions, 82.5% ± 23.6% (mean ± SD; Figure 4B) of clones formed AR-positive calcium deposits (Figure 4D; one representative clone shown). We conclude that the majority of fetal CD34<sup>−</sup>CD56<sup>int</sup>ITGA<sub>7</sub>hi hMFA cells possess bipotent myogenic and osteogenic differentiation potential in these in vitro assays.

To further investigate the potential of fetal CD34<sup>−</sup>CD56<sup>int</sup>ITGA<sub>7</sub>hi cells, we determined their expression of myogenic and osteogenic lineage genes at the end of clonal expansion and after myogenic or osteogenic differentiation (Figure 4A). All (four out of four) CD34<sup>−</sup>CD56<sup>int</sup>ITGA<sub>7</sub>hi cell-derived clones analyzed by quantitative RT-PCR (qRT-PCR) expressed both myogenic (MYOD and DESMIN; Figures 4E and 4F) and osteogenic (RUNX2, OSTERIX/SP7, and OSTEOCALCIN/BGLAP; Figures 4G–4I) genes. Osteogenic lineage gene expression at the end of in vitro clonal expansion and after myogenic or osteogenic differentiation corroborated the osteogenic activity of human fetal CD34<sup>−</sup>CD56<sup>int</sup>ITGA<sub>7</sub>hi cells. Expression of BGLAP increased significantly in cells that underwent osteogenic differentiation compared to proliferating clones; however, BGLAP did not increase in cells that underwent myogenic differentiation (Figure 4I). Increased expression of RUNX2 and SP7 in CD34<sup>−</sup>CD56<sup>int</sup>ITGA<sub>7</sub>hi cells after osteogenic differentiation in vitro was variable between clones and did not reach statistical significance (Figures 4G–4I).
Importantly, at least some CD34\(^+\)/CD56\(^{int}\)ITGA7\(^{hi}\) cells exposed to osteogenic differentiation conditions maintained myogenic activity as evidenced by an increase in \textit{DESMIN} expression during osteogenic culture (Figures 4F) and the presence of multinucleated myotubes in these cultures (data not shown).

**Human Fetal CD34\(^+\)/CD56\(^{int}\)ITGA7\(^{hi}\) Cells Engraft Myofibers when Transplanted into Mouse Skeletal Muscle**

To assess the contributions of FACS-isolated fetal hMFA cells to muscle regeneration in vivo, we adapted previously published protocols to detect engraftment of unfractionated human myogenic cells in mouse muscle (Ehrhardt et al., 2007). Freshly isolated cells were injected directly into the cardiotoxin preinjured tibialis anterior muscles of immunodeficient nonobese diabetic severe combined immunodeficiency interleukin-2\(^{-}\)/mice (NSG) mice, transplanted muscles were harvested 3–8 weeks after transplantation, and engraftment of human cells was detected by staining with antibodies against the human membrane protein SPECTRIN (h-SPECTRIN). H-SPECTRIN staining was strongly positive in fetal human muscle sections (Figure 5A, left panel) and uniformly
**Figure 5. In Vivo Engraftment of Fetal hMFA Cell Subsets in Mouse Muscle**

Engrafted hMFA cells were detected in transplanted NSG mouse muscle by costaining for human species-specific h-SPECTRIN (h-SPEC, red), muscle-specific DYSTROPHIN (DYS, green), and DAPI (blue).

(A) Species-specific staining for h-SPEC is strongly positive in human muscle (left) and absent in mouse muscle (middle). Unfractionated hMFA cells engrafted to form h-SPEC-positive cells in four out of four transplanted mice (right).

(legend continued on next page)
absent in mouse muscle sections (Figure 5A, middle panel). Engraftment of unFractionated fetal hMFA cells, as evidenced by the presence of h-SPECTRIN+ cells on serial sections of transplanted muscles, was detected in four out of four transplanted mice (injected with 900,000 cells per mouse, isolated from two donors in two independent experiments; Figure 5A, right panel). To assess the in vivo myogenic activity of sorted fetal hMFA cell subsets, cells were isolated from 11 individual donors and transplanted into the cardiotoxin preinjured tibialis anterior muscles of NSG recipients. Engraftment by human cells, marked by staining with h-SPECTRIN, was detected in 6 of 28 muscles transplanted with CD34+CD56intITGA7hi fetal hMFA cells (37,000–100,000 cells injected), 8 of 25 muscles transplanted with CD34+ fetal cells (37,000–100,000 cells injected), three of ten muscles transplanted with CD34+/lowCD56 ITGA7low fetal cells (20,000–100,000 cells injected), and three of ten muscles transplanted with CD34+CD56intITGA7low fetal cells (7,000–100,000 cells injected) (Figure 5B, top panels, and Figure 5C). Similar numbers of h-SPECTRIN-positive cells were detected in muscles transplanted with human CD34+CD56intITGA7hi fetal hMFA cells (12 ± 3; mean ± SEM), CD34+ cells (8 ± 3; mean ± SEM), CD34+/lowCD56 ITGA7low cells (11 ± 5; mean ± SEM), or CD34+CD56intITGA7low cells (5 ± 2; mean ± SEM) (Figure 5D).

We next evaluated myogenic engraftment of fetal hMFA cell subsets in transplanted mouse muscles by costaining for h-SPECTRIN (Figure 5B, top panels) and DYSTROPHIN (Figure 5B, middle panels), a membrane protein expressed in both mouse and human muscle fibers. Costaining of h-SPECTRIN and DYSTROPHIN (Figure 5B, bottom panels, and Figure 5S) in four of six muscles engrafted with fetal human CD34+CD56intITGA7hi cells indicated that the transplanted cells underwent myogenic differentiation and contributed to the formation of mature fibers. A total of 35%–100% of h-SPECTRIN+ cells in these muscles coexpressed DYSTROPHIN. In contrast, none (0%) of the h-SPECTRIN+ cells detected in muscles engrafted with fetal CD34+ cells, CD34+/lowCD56 ITGA7low cells, or CD34+CD56intITGA7low cells were DYSTROPHIN+ (Figure 5E). Thus, only fetal CD34+CD56intITGA7hi hMFA cells are capable of myogenic engraftment in mouse muscle.

The Transcriptional Signatures of Fetal hMFA Cell Subsets Are Consistent with Lineage-Specific Differences in Their Differentiation Capacities

To gain deeper insights into the molecular underpinnings of CD34+CD56intITGA7hi and CD34+ adipogenic progenitors within the fetal hMFA cell pool, the transcriptional profile of these functionally distinct populations, as compared to unFractionated fetal hMFA cells, was evaluated. Principal component analysis (PCA; Figure 6A) and hierarchical cluster analysis (Figure 6B) showed clustering of CD34+ CD56intITGA7hi cells, CD34+ cells, and hMFA cells into three transcriptionally distinct populations. Comparison of CD34+CD56intITGA7hi cells (12.2% ± 4.3% of live fetal hMFA cells; Table S1) to unFractionated hMFA cells identified 5,686 differentially regulated probesets, and comparison of CD34+ cells (62.7% ± 7.8% of live fetal hMFA cells; Table S1) to unFractionated hMFA cells yielded 1,029 differentially regulated probesets (>1.5-fold difference up or down and p < 0.05). Notably, there was no overlap between these groups of differentially regulated genes. Ingenuity pathway analysis revealed that within the group of genes most highly upregulated in fetal CD34+CD56intITGA7hi cells as compared to CD34+ cells (>5-fold difference, p < 0.01, total 346 genes; Table S2), the 25 top-scoring functions involved muscle development, differentiation, or function (Table S3). Interestingly, within the group of genes most highly upregulated in CD34+ cells versus CD34+CD56intITGA7hi cells (>5-fold difference, p < 0.01, total 854 genes; Table S4), the seven top-scoring functions involved solid tumor malignancy (Table S5).

We also specifically analyzed expression by freshly isoFractionated fetal CD34+CD56intITGA7hi cells and CD34+ cells of certain myogenic lineage (PAX7, MYF5, M-CADHERIN/CDH15, MYOD, MYOG), adipogenic lineage (PPARG, FABP4) and osteogenic lineage (COLIA, ALPL, BGLAP, RUNX2) genes in the microarray data set (Figure 6C). Expression of satellite cell markers (including the HGF receptor MET; Figure S6C) and myogenic genes was upregulated in fetal CD34+CD56intITGA7hi hMFA cells, whereas adipogenic genes were upregulated in fetal CD34+ cells (Figure 6C). Expression of osteolineage genes was detected in both CD34+CD56intITGA7hi cells and CD34+ cells (Figure 6C), consistent with the osteogenic activity of both populations. Finally, we confirmed differential

(B) Engrafted fetal CD34+CD56intITGA7hi hMFA cells formed myofibers as demonstrated by costaining for h-SPEC and DYS. Engrafted CD34+, CD34+CD56intITGA7, and CD34+/lowCD56 ITGA7low cells formed h-SPEC+, DYS+ cells.
(C) Engraftment efficiency was calculated for each subset as the number of muscles engrafted (i.e., h-SPEC+ cells present) of all muscles transplanted.
(D) Engraftment was quantified as the maximum number of h-SPEC+ cells per engrafted muscle section. Data are mean ± SEM.
(E) Myogenic engraftment was quantified as the percentage of h-SPEC+ cells that were also DYS+. Statistical significance was evaluated by unpaired, two-tailed t test (*p < 0.05; **p < 0.001; ns, not significant). Data are mean ± SEM.
See also Figure S5.
expression of adipogenic, osteogenic, and myogenic lineage-specific genes (PPARG, FABP4, BGLAP, RUNX2, PAX7, and MYF5) in fetal CD34−CD56intITGA7hi and CD34+ hMFA cells by qRT-PCR (Figure 6D). Levels of PPARG (fold-change $-47 \pm 20$), FABP4 (fold-change $-10 \pm 2$) and BGLAP (fold-change $-4 \pm 3$) were reduced in CD34+CD56intITGA7hi cells compared to CD34+ cells. In contrast, PAX7 (fold-change $+513 \pm 70$) and MYF5 (fold-change $+674 \pm 31$) levels were increased in CD34−CD56intITGA7hi cells, consistent with their myogenic function. Thus, sorted CD34−CD56intITGA7hi cells and CD34+ cells from fetal human muscle possess transcriptional signatures highly consistent with their distinct differentiation potentials.
Finally, our microarray analyses identified a number of additional surface markers as differentially regulated in fetal CD34+/CD56intITGA7hi and CD34+ hMFA cells, including increased levels of MCAM (Figure S6B), CD144 (Figure S6B), and PROMININ1 (CD133; Figure S6B) and decreased levels of PDGFRA (CD140a; previously reported to mark adipocyte precursors; Berry and Rodeheffer, 2013; Figure S6B) in CD34+CD56intITGA7hi as compared to CD34+ cells (Table S6).

**Adult Skeletal Muscle Shows Reduced Content of PAX7-Expressing CD34+CD56intITGA7hi hMFA Cells with Myogenic and Osteogenic Activity**

To determine whether the surface marker combination we identified as marking PAX7-expressing osteogenic/myogenic progenitors in human fetal muscle would similarly mark progenitors in adult tissue, we evaluated differential expression of surface markers (Figure 7A), PAX7 enrichment (Figure 7B), myogenic differentiation (Figure 7C), and osteogenic differentiation (Figure S7) in hMFA cells obtained from discarded human adult muscle.

FACS analysis indicated clear separation of CD34+ and CD34+/low subsets within the pool of viable CD45−CD11b−GlyA−CD31− adult hMFA cells (Figure 7A). As in fetal muscle, all myogenic activity was contained within the CD34+/low subset of adult hMFA cells, whereas CD34+ cells were uniformly nonmyogenic (Figure 7C). However, within the CD34+/low adult hMFA cell pool, expression of CD56 and ITGA7 discriminated only two cell populations: CD34+/lowCD56intITGA7low and CD34+/CD56intITGA7hi cells. The CD34+/CD56intITGA7low subset detected in fetal muscle was not present in adult muscle (Figure 7A). We confirmed selective enrichment of PAX7-expressing cells (89% ± 7%, mean ± SD; Figure 7B) and in vitro myogenic activity (Figure 7C, second panel from right) in adult CD34+CD56+/lowITGA7hi hMFA cells. Finally, analogous to fetal cells, adult CD34+CD56+/lowITGA7hi cells exhibited osteogenic activity (Figure S7A) and lacked adipogenic potential (Figure S7B) in vitro, in addition to their myogenic function. Thus, CD34+CD56+/lowITGA7hi hMFA cells isolated from adult muscle, similar to cells of the same marker phenotype obtained from fetal muscle, are PAX7-expressing cells with osteogenic/myogenic activity. However, total hMFA cell numbers were significantly lower in adult muscle (mean of 0.4 × 10^6 [adult] versus 2.5 × 10^6 [fetal] hMFA cells per gram muscle; p = 0.0001; Figure 7D), and the percentage of CD34+CD56+/lowITGA7hi cells among hMFA cells was also lower (mean of 12.2% ± 1.7% [fetal] versus 1.5% ± 1.7% [adult]; p < 0.0001; Figure 7F). This translated into an ~2-log reduction in the total number of CD34+CD56+/lowITGA7hi hMFA cells in adult as compared to fetal muscle (mean 3.3 × 10^5 [fetal] versus 3.6 × 10^5 [adult] cells per gram of muscle; p = 0.0002; Figure 7E).

**DISCUSSION**

Recent advances enabling the prospective isolation of mouse satellite cells have facilitated mechanistic analyses of their myogenic function. For example, the ability to clonally sort satellite cells with high purity made possible the demonstration that these cells can undergo asymmetric division (Kuang et al., 2007; Rocheteau et al., 2012) and repopulate the satellite cell niche in vivo (Cerletti et al., 2008). While findings in mouse models are often extrapolated to human biology, whether mouse and human myogenic cells exhibit fully equivalent properties may still be questioned, particularly given significant phenotypic discrepancies in several mouse models of human muscle disease (Bullfield et al., 1984). All of these issues can be addressed through the establishment of robust methods for direct purification of human muscle progenitors.

Previous work by Pisani et al. demonstrated the utility of the sialomucin CD34 to enrich for myogenic cells within the CD34− subset of magnetically separated cells in adult muscle (Pisani et al., 2010b), consistent with immunohistochemical studies reporting the absence of CD34 in adult human muscle cells located in the satellite cell position (Lecourt et al., 2010). Pisani et al. also noted mixed myogenic and adipogenic activity within CD34+ adult muscle cells, which showed differential expression of CD56 (Pisani et al., 2010a). Findings from our study confirm that CD34 distinguishes myogenic and nonmyogenic cells within the nonhematopoietic, nonendothelial (CD45−CD11b−GlyA−CD31−) hMFA cell pool in both fetal and adult tissue: CD34+ cells are PAX7-negative, adipogenic cells that do not possess any myogenic activity, whereas within the CD45−CD11b−GlyA−CD31−CD34−/low subset, selection of CD56+/lowITGA7hi hMFA cells yields a highly enriched population of PAX7-expressing, robustly myogenic progenitors. Yet, it is important to note that these FACS-based strategies pertain to cells isolated from fresh muscle only. Sorted cells may undergo marked changes in their surface marker profiles during ex vivo culture, and it is unclear if our protocols are applicable to cells that have undergone expansion/differentiation in culture.

Fluorescence-activated cell-sorted fetal human CD34+CD56+/lowITGA7hi cells engraft in mouse muscle to form new myofibers, albeit at low efficiency (Figures 5B–5F). Low-level engraftment of human cells into mouse tissue is not unexpected, as similar outcomes have been observed for other human, tissue-specific stem and progenitor cells upon transfer into immune-compromised mice (Doulavov
Figure 7. Adult CD34^+CD56^intITGA7^hi hMFA Cells Are PAX7-Expressing Myogenic Progenitors

(A) FACS gating strategy for isolation of CD45^-CD11b^-GlyA^-CD31^-CD34^-CD56^intITGA7^hi cells within live (7AAD^- Calcein^+) hMFA cells.

(B) PAX7 expression (red) is enriched in CD34^+CD56^intITGA7^hi hMFA cells (89% ± 7% [mean ± SD] Pax7^+), as assessed by IF. Nuclei were marked by DAPI (blue).

(legend continued on next page)
et al., 2012; Racki et al., 2010). Unfortunately, given the relatively sparse presence of human myofibers in this system, we were unable to establish conditions to reliably detect costaining for PAX7 and human species-specific nuclear antigens on engrafted mouse muscle sections. We therefore were unable to determine if fluorescence-activated cell sorted fetal human CD34+/CD56intITGA7hi cells can repopulate the PAX7-expressing satellite cell pool in vivo. We also were unable to test the in vivo engraftment potential of fluorescence-activated cell-sorted cell-sorted progenitors from adult human muscle, given the low yield of cells that could be obtained from adults (Figure 7E).

Interestingly, enrichment of PAX7 expression and myogenic activity within the CD34+ compartment in human muscle stands in contrast to immunophenotyping studies in mouse muscle, which localize myogenic activity to the CD34+ subset of mouse MFA cells (Beauchamp et al., 2000; Conboy et al., 2010; Montarras et al., 2005; Sacco et al., 2008; Sherwood et al., 2004). Species-specific differences in CD34 expression have also been noted in other somatic stem cell populations, including hematopoietic stem cells (HSCs), which are CD34+ in adult human bone marrow and CD34− in adult mouse bone marrow (Okuno et al., 2002; Osawa et al., 1996). Such differences appear to arise from the presence of species-specific upstream regulatory elements, which differentially regulate CD34 gene transcription in mouse and human cells (Okuno et al., 2002).

Cell surface markers that have proved useful for the isolation of mouse PAX7+ satellite cells include ITGA7 (Pasut et al., 2012; Sacco et al., 2008), CXCR4 and β1 INTEGRIN (Sherwood et al., 2004), and VCAM1 (Chakkalakal et al., 2012). Our studies indicate that PAX7-expressing cells in fetal and adult human muscle coexpress ITGA7 and CD56, although neither of these markers alone is sufficient to distinguish these cells. This is consistent with ITGA7 and CD56 expression by human myogenic progenitors derived from PAX7-expressing induced pluripotent stem cells (Darabi et al., 2012). Clear expression of CXCR4 was observed in adult and fetal PAX7-expressing cells (Figure S6A), and β1-INTEGRIN was detected on 90% of hMFA cells (Figure 1B). Additional surface marker analyses, focusing particularly on those previously linked to mouse and/or human myogenic precursors (Cerletti et al., 2012; Darabi et al., 2012; Lecourt et al., 2010; Zheng et al., 2007), revealed increased expression of MCAM (CD146) and CD44 in human fetal CD34+CD56intITGA7hi cells as compared to CD34+ cells (Figure S6B). Finally, our microarray analyses suggest that PROMININ1 (CD133) and PDGFRα (CD140a; previously reported to mark adipocyte precursors; Berry and Rodeheffer, 2013) could also be useful in distinguishing human myogenic progenitors, as they are differentially expressed in fetal CD34−CD56intITGA7hi cells and CD34+ cells (Figure S6C; Table S6).

MFA cells obtained from mouse and human muscle were previously shown to exhibit osteogenic activity (Glass et al., 2011; Hashimoto et al., 2008; Lecourt et al., 2010; Oishi et al., 2013). In our studies, both fetal and adult PAX7-expressing CD34−CD56intITGA7hi cells formed AR-positive calcium deposits and expressed osteogenic lineage genes under osteogenic conditions, consistent with prior reports of osteogenic differentiation potential within the pool of muscle cells containing PAX7+ progenitors (Hashimoto et al., 2008; Ozeki et al., 2006). Clonal assays revealed that the osteogenic activity of human fetal CD34−CD56intITGA7hi hMFA cells is unlikely to be attributable to contamination by other cells, as the majority of clone-sorted cells exhibited bipotent myogenic and osteogenic activity. Future studies are needed to investigate adult muscle progenitor bipotency and delineate the events that trigger possible osteogenic differentiation of human CD34−CD56intITGA7hi cells, their possible contributions to normal bone regeneration, and their relationship to other mesenchymal precursor cells.

In contrast to fetal CD34−CD56intITGA7hi cells, which exhibit robust myogenic activity and lack adipogenic potential, human fetal CD34+ cells are adipogenic and lack myogenic capacity. While our studies evaluated the ability of these cells to form white adipocytes, a previous report indicates that CD34+ cells in fetal and adult human muscle contain brown adipogenic activity as well (Crisan et al., 2008). Gene expression profiling confirms profound differences in the transcriptional signatures of fetal human CD34−CD56intITGA7hi and CD34+ hMFA cells, with increased expression of muscle lineage genes in CD34−CD56intITGA7hi cells and increased expression of adipogenic genes in CD34+ cells. Given their differentiation profile, we speculate that CD34+ hMFA cells may represent the human counterparts of the fibroadipogenic precursor (FAP) population in mouse muscle (Joe et al., 2010; Uezumi et al., 2010), an important subset of nonmyogenic cells that appears to enhance muscle regenerative capacity (Joe et al., 2010).

(C) Myogenic differentiation assays showed that in vitro myogenic activity is highly enriched in adult CD34−CD56intITGA7hi cells and absent from CD34+ and CD34−/lowCD56−/low ITGA7hi cells.

(D–F) Numbers of hMFA cells (D) or CD34−CD56intITGA7hi cells (E) per gram of tissue, and frequency of CD34−CD56intITGA7hi cells (F), were compared for adult and fetal muscle. Statistical significance was evaluated by unpaired, two-tailed t test. Data are mean ± SD. See also Figure S7.
In summary, we report functionally distinct cell populations within the hMFA cell pool in fetal and adult muscle and provide a specific method for the prospective isolation of purified PAX7+ cells from human muscle. We anticipate that this technology will facilitate novel insights into human muscle homeostasis, aging, and disease. Phenotypically distinct cells with myogenic progenitor function also represent promising targets for muscle regenerative cell therapy and could conceivably be used to treat a variety of diseases, including muscular dystrophy and muscle injuries.

EXPERIMENTAL PROCEDURES

Human Skeletal Muscle Specimens
Human fetal muscle was obtained from 20- to 23-week-gestation fetuses and adult muscle from deceased volunteers or discarded during surgery (Table S1). Use of human tissues was approved by relevant institutional review boards.

Isolation of hMFA Cells
hMFA cells were isolated by two-step enzymatic digestion and mechanical dissociation as per previously published protocols (Sherwood et al., 2004).

Antibody Staining and FACS
Primary and secondary antibodies used for FACS are listed in Table S7. All cell populations were sorted twice to maximize purity.

PAX7 IF and Quantification
hMFA cell subsets were sorted directly into 40 µl of PBS spotted on a glass slide (5 x 10^3 cells per slide) according to protocols adapted from (Ema et al., 2006). Sorted cells were stained with PAX7 (DSHB, 10 µg/ml).

Myogenic Differentiation Assay
hMFA cell subsets were sorted in 96-well plates, expanded in myogenic growth medium for 7 days, transitioned into differentiation medium for 4–5 days, and fixed and stained with DESMIN antibody (clone D33, M0760, titer 1:50; Dako).

Adipogenic Differentiation Assay
hMFA cell subsets were sorted in 96-well plates, expanded in adipogenic growth medium until confluent (13–14 days), transitioned into adipogenic induction medium for 3 days, placed in differentiation medium for 4 days, and fixed and stained with ORO (Sigma).

Osteogenic Differentiation Assay
hMFA cell subsets were sorted in 96-well plates, expanded in preadipocyte medium (PM-1, ZenBio) + 25 ng/ml basic fibroblast growth factor (Sigma) until confluent (13–14 days), transitioned into osteoblast differentiation medium (OB-1, ZenBio) for 14 days, and fixed and stained with 2% AR (Sigma).

Clonal Cell Culture
Fetal hMFA cell subpopulations were sorted at 1 cell per well in 96-well plates in myogenic growth medium. After 9–10 days, the number of wells with visible cell growth was determined. Cells were kept in myogenic growth conditions until confluent and passaged into myogenic or osteogenic differentiation assays.

Transplantation Studies
NSG mice (Jackson Laboratory) were bred and maintained at Joslin Diabetes Center under Institutional Animal Care and Use Committee-approved protocols. The tibialis anterior (TA) muscle of 6- to 8-week-old NSG mice was conditioned 24 hr prior to transplantation by injection of 25 µl (0.03 mg/ml) of Naja mossambica mossambica cardiotoxin (CTX, Sigma). Recipient muscles were harvested 3–8 weeks after transplantation. Engraftment was evaluated by IF staining of 7 µm sections for h-SPECTRIN (human species-specific) and DYSTROPHIN. Tissue was blocked using Papain-digested RAM antibodies supplemented with goat Fc antibodies at 5 µg/ml and 5% fetal bovine serum according to previously published protocols (Ehrhardt et al., 2007).

Microarray Analysis
Total RNA was extracted using TRIzol labeled and hybridized to Affymetrix microarrays (Human Genome U133 Plus 2.0). Raw data were normalized and differentially regulated probesets were identified using GenePattern. Hierarchical clustering was performed in GenePattern (Broad Institute), PCA using 3D-PCA, and pathway analysis using Ingenuity.

PCR
Total RNA was extracted using TRIzol, reverse transcribed using Superscript III First-Strand Synthesis System (Invitrogen). qRT-PCR was performed using an AV7900 PCR system (Applied Biosystems) and TaqMan Gene Expression Assays (Invitrogen).

Statistics
Statistical analysis was performed using two-tailed Student’s t test for unpaired data when appropriate. p values are indicated with asterisks (*p < 0.05, **p < 0.001, and ***p < 0.0001) and NS (not significant).

For additional details regarding experimental procedures, please see the Supplemental Experimental Procedures.

ACCESSION NUMBERS
The microarray data reported in this paper were deposited in the NCBI Gene Expression Omnibus under accession number GSE44227.

SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures, seven figures, and seven tables and can be found with this article online at http://dx.doi.org/10.1016/j.stemcr.2013.12.006.
 ACKNOWLEDGMENTS

We thank Perrin Larton and her staff at Advanced Bioscience Resources (ABR, Alameda, CA) as well as the staff at the National Development and Research Institutes (NDRI, Philadelphia, PA). We thank A. Wakabayashi, G. Buruzula, and J. LaVecchio at Joslin's HSCI/DRC Flow Cytometry Core (NIH P30DK036836), Katelyn Hughes at Joslin's DRC Genomics Core (NIH P30DK036836), the Biopolymers Facility Service at Harvard Medical School for BioAnalyzer evaluation of RNA, and C. Vernochet for assistance with adipogenic and osteogenic differentiation assays. This work was funded in part by a pilot grant from the Boston Claude D. Pepper Center (NIH 5P30AG031679 to S.H.) and grants from P.A.L.S. Bermuda/St. Baldrick's (to S.H.); by grants from the Burroughs-Welcome Fund, Harvard Stem Cell Institute, and Beckman Foundation; and by a Stand Up To Cancer-American Association for Cancer Research Innovative Research Grant (SU2C-AACR-IRG1111) (to A.J.W.). A.C. conducted this study as partial fulfillment of her PhD in Molecular Medicine, Program in Preventive and Predictive Medicine, San Raffaele University, Milan, Italy. A.J.W. is an Early Career Scientist of the Howard Hughes Medical Institute. Content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or other funding agencies.

Received: May 5, 2013
Revised: December 4, 2013
Accepted: December 5, 2013
Published: January 9, 2014

REFERENCES


